Desflurane
Active ingredient: Desflurane
In short: Desflurane USP, liquid for inhalation is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. Desflurane USP, liquid for inhalation is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a hig
What is Desflurane used for?
Desflurane USP, liquid for inhalation is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults.
Desflurane USP, liquid for inhalation is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events.
Desflurane USP, liquid for inhalation is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients.
After induction of anesthesia with agents other than Desflurane USP, liquid for inhalation and tracheal intubation, Desflurane USP, liquid for inhalation is indicated for maintenance of anesthesia in infants and children.
Desflurane USP, liquid for inhalation is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions
.
Desflurane dosage
Only persons trained in the administration of general anesthesia should administer Desflurane. Only a vaporizer specifically designed and designated for use with desflurane should be utilized for its administration. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available.
Desflurane administered by inhalation. The administration of general anesthesia must be individualized based on the patient's response. Hypotension and respiratory depression increase as anesthesia with desflurane is deepened. The minimum alveolar concentration (MAC) of desflurane decreases with increasing patient age. The MAC for Desflurane is also reduced by concomitant N
2O administration (
see Table 1). The dose should be adjusted accordingly. The following table provides mean relative potency based upon age and effect of N
2O in predominately ASA physical status I or II patients.
Benzodiazepines and opioids decrease the MAC of Desflurane
. .
Desflurane also decreases the doses of neuromuscular blocking agents required
.The dose should be adjusted accordingly.
Table 1
Effect of Age on Minimum Alveolar Concentration of Desflurane
Mean ± SD (percent atmospheres)
Age | N | O
2 100% | N | N
2O 60% / 40% O
2
2 weeks | 6 | 9.2 ± 0.0 | - | -
10 weeks | 5 | 9.4 ± 0.4 | - | -
9 months | 4 | 10.0 ± 0.7 | 5 | 7.5 ± 0.8
2 years | 3 | 9.1 ± 0.6 | - | -
3 years | - | - | 5 | 6.4 ± 0.4
4 years | 4 | 8.6 ± 0.6 | - | -
7 years | 5 | 8.1 ± 0.6 | - | -
25 years | 4 | 7.3 ± 0.0 | 4 | 4.0 ± 0.3
45 years | 4 | 6.0 ± 0.3 | 6 | 2.8 ± 0.6
70 years | 6 | 5.2 ± 0.6 | 6 | 1.7 ± 0.4
N = number of crossover pairs (using up-and-down method of quantal response)
Issues such as whether or not to premedicate and the choice of premedication(s) must be individualized. In clinical studies, patients scheduled to be anesthetized with Desflurane frequently received IV preanesthetic medication, such as opioid and/or benzodiazepine.
In adults, some premedicated with opioid, a frequent starting concentration was 3% Desflurane increased in 0.5-1.0% increments every 2 to 3 breaths. End-tidal concentrations of 4-11%, Desflurane with and without N
2O, produced anesthesia within 2 to 4 minutes. When Desflurane was tested as the primary anesthetic induction agent, the incidence of upper airway irritation (apnea, breathholding, laryngospasm, coughing and secretions) was high. During induction in adults, the overall incidence of oxyhemoglobin desaturation (SpO
2< 90%) was 6% .
After induction in adults with an intravenous drug such as thiopental or propofol, Desflurane can be started at approximately 0.5-1 MAC, whether the carrier gas is O
2or N
2O/O
2. …
How to take Desflurane — instructions & advice from the label
Anesthesia providers need to obtain the following information from patients prior to administration of anesthesia:
• Medications they are taking, including herbal supplements
• Drug allergies, including allergic reactions to anesthetic agents (including hepatic sensitivity)
• Any history of severe reactions to prior administration of anesthetic
• If the patient or a member of the patient’s family has a history of malignant hyperthermia or if the patient has a history of Duchenne muscular dystrophy or other latent neuromuscular disease
Anesthesia providers should inform patients of the risks associated with Desflurane:
• Post-operative nausea and vomiting and respiratory adverse effects include coughing.
• There is no information of the effects of Desflurane following anesthesia on the ability to operate an automobile or other heavy machinery. However, patients should be advised that the ability to perform such tasks may be impaired after receiving anesthetic agents.
Anesthesia providers should inform parents and caregivers of pediatric patients that emergence from anesthesia in children may evoke a brief state of agitation that may hinder cooperation. …
Warnings & precautions
Do not take this medicine if: The use of Desflurane is contraindicated in the following conditions:
• Known or suspected genetic susceptibility to malignant hyperthermia
.
• Patients in whom general anesthesia is contraindicated.
• Induction of anesthesia in pediatric patients.
• Patients with known sensitivity to Desflurane or to other halogenated agents .
• Patients with a history of moderate to severe hepatic dysfunction following anesthesia with Desflurane or other halogenated agents and not otherwise explained .
In susceptible individuals, volatile anesthetic agents, including desflurane, may trigger malignant hyperthermia, a skeletal muscle hypermetabolic state leading to high oxygen demand. Fatal outcomes of malignant hyperthermia have been reported.
The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. Desflurane can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (
RYR1) or dihydropyridine receptor (
CACNA1S) variants.
Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia, hypercapnia, muscle rigidity (e.g., jaw muscle spasm), tachycardia (e.g., particularly that unresponsive to deepening anesthesia or analgesic medication administration), tachypnea, cyanosis, arrhythmias, hypovolemia, and hemodynamic instability. Skin mottling, coagulopathies, and renal failure may occur later in the course of the hypermetabolic process.
Successful treatment of malignant hyperthermia depends on early recognition of the clinical signs. …
Desflurane side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse event information is derived from controlled clinical trials, the majority of which were conducted in the United States. The studies were conducted using a variety of premedications, other anesthetics, and surgical procedures of varying length. Most adverse events reported were mild and transient, and may reflect the surgical procedures, patient characteristics (including disease) and/or medications administered.
Of the 2,143 patients exposed to Desflurane in clinical trials, 370 adults and 152 children were induced with desflurane alone and 987 patients were maintained principally with desflurane. The frequencies given reflect the percent of patients with the event. Each patient was counted once for each type of adverse event. They are presented in alphabetical order according to body system.
Table 2
Frequency of Events Occurring in Greater Than 1% of Clinical Trial Patients
(in Reports Deemed “Probably Causally Related”)
Induction (use as a mask inhalation agent)
Adult Patients (N=370): | Coughing 34%, breathholding 30%, apnea 15%,
increased secretions*, laryngospasm*, oxyhemoglobin desaturation
(SpO 2< 90%)*, pharyngitis*. …
Drug interactions
No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials. The effect of Desflurane on the disposition of other drugs has not been determined. Similar to isoflurane, Desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.
Benzodiazepines and opioids decrease the amount of desflurane (MAC) needed to produce anesthesia. This effect is shown in Table 3 for intravenous midazolam (25-50 mcg/kg) and intravenous fentanyl (3-6 mcg/kg) in patients of two different age groups.
Table 3
Desflurane MAC with Fentanyl or Midazolam
Mean ± SD (percent reduction)
Dose | 18-30 years | 31-65 years
No fentanyl | 6.4 ± 0.0 | 6.3 ± 0.4
3 mcg/kg fentanyl | 3.5 ± 1.9 (46%) | 3.1 ± 0.6 (51%)
6 mcg/kg fentanyl | 3.5 ± 1.9 (46%) | 2.3 ± 1.0 (64%)
No midazolam | 6.9 ± 0.1 | 5.9 ± 0.6
25 mcg/kg midazolam | - | 4.9 ± 0.9 (16%)
50 mcg/kg midazolam | - | 4.9 ± 0.5 (17%)
Anesthetic concentrations of desflurane at equilibrium (administered for 15 or more minutes before testing) reduced the ED
95 of succinylcholine by approximately 30% and that of atracurium and pancuronium by …
About this medicine
Desflurane USP, liquid for inhalation a nonflammable liquid administered via vaporizer, is a general inhalation anesthetic. It is (±)1,2,2,2-tetrafluoroethyl difluoromethyl ether:
Some physical constants are:
Molecular weight 168.04
Specific gravity (at 20°C/4°C) 1.465
Vapor pressure in mm Hg 669 mm Hg @ 20°C
731 mm Hg @ 22°C
757 mm Hg @ 22.8°C (boiling point;1atm)
764 mm Hg @ 23°C
798 mm Hg @ 24°C
869 mm Hg @ 26°C
Partition coefficients at 37°C:
Blood/Gas 0.424
Olive Oil/Gas 18.7
Brain/Gas 0.54
Mean Component/Gas Partition Coefficients:
Polypropylene (Y piece) 6.7
Polyethylene (circuit tube) 16.2
Latex rubber (bag) 19.3
Latex rubber (bellows) 10.4
Polyvinylchloride (endotracheal tube) 34.7
Desflurane USP, liquid for inhalation is nonflammable as defined by the requirements of International Electrotechnical Commission 601-2-13.
Desflurane USP, liquid for inhalation is a colorless, volatile liquid below 22.8°C. Data indicate that Desflurane USP, liquid for inhalation is stable when stored under normal room lighting conditions according to instructions. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 80883017-6797-43b2-a500-36843e7e1aff. Read the full official label on DailyMed.